Article Versions Notes

Tomita Y, Sakata S, Imamura K, Iyama S, Jodai T, Saruwatari K, Hamada S, Akaike K, Anai M, Fukusima K, et al. Association of Clostridium butyricum Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations. Cancers. 2024; 16(1):47. https://doi.org/10.3390/cancers16010047

Tomita, Yusuke, Shinya Sakata, Kosuke Imamura, Shinji Iyama, Takayuki Jodai, Koichi Saruwatari, Shohei Hamada, Kimitaka Akaike, Moriyasu Anai, Kazuaki Fukusima, and et al. 2024. "Association of Clostridium butyricum Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations" Cancers 16, no. 1: 47. https://doi.org/10.3390/cancers16010047

Tomita, Y., Sakata, S., Imamura, K., Iyama, S., Jodai, T., Saruwatari, K., Hamada, S., Akaike, K., Anai, M., Fukusima, K., Takaki, A., Tsukamoto, H., Goto, Y., Motozono, C., Sugata, K., Satou, Y., Ueno, T., Ikeda, T., & Sakagami, T. (2024). Association of Clostridium butyricum Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations. Cancers, 16(1), 47. https://doi.org/10.3390/cancers16010047